Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 12/20 | 0.65 |
| ▸ | F10 | P00742 | 11/20 | 0.65 |
| ▸ | PLG | P00747 | 12/20 | 0.62 |
| ▸ | ST14 | Q9Y5Y6 | 8/20 | 0.57 |
| ▸ | F2 | P00734 | 7/20 | 0.57 |
| ▸ | HPN | P05981 | 3/20 | 0.56 |
| ▸ | PLAT | P00750 | 3/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.55 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2874625 | 0.84 | PLAU (0.80) | PLAUF10PLGST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL4606324 | 0.83 | PLAU (0.80) | PLAUF10PLGST14F2 | |
| SCHEMBL4588726 | 0.77 | F10 (0.55) | PLAUF10PLGST14F2 | |
| SCHEMBL14669451 | 0.77 | F10 (0.71) | PLAUF10PLGST14F2 | |
| SCHEMBL14669448 | 0.76 | F10 (0.70) | PLAUF10PLGST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL1809303 | 0.76 | PLAU (0.67) | PLAUF10PLGST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2875164 | 0.74 | PLAU (0.65) | PLAUF10PLGST14F2 | |
| SCHEMBL8914454 | 0.74 | P2RX7 (0.51) | PLAUF10PLGF2 | |
| SCHEMBL22871389 | 0.73 | POLB (0.58) | PLAUF10PLGF2 | |
| SCHEMBL8913765 | 0.73 | F2 (0.49) | PLAUF10PLGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624169-B1 | 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases targeting lymphocytes and for treating disorders of the lymphatic tissue, in particular lymphomas. | WILEX BIOTECHNOLOGY GMBH (DE) | 2003-09-23 | — | — | US | disclosed |